Comparison of the Sysmex XT-2000iV with microscopic differential counts of canine bone marrow.
Canine bone marrow is frequently assessed in the advanced preclinical research environment. Automated analysis provides time savings and objectivity over the gold standard of microscopic (cytologic) evaluation. We compared the analysis of 90 canine bone marrow samples by the Sysmex XT-2000iV hematology analyzer (Sysmex Corp., Kobe, Japan) with cytologic evaluation. Gates for cell populations were created in the system's WBC/BASO channel. Variables "total nucleated red blood cells" (total_NRBC), "poly- and orthochromatic nucleated red blood cells" (poly_orth_NRBC), "total neutrophils" (total_NEUT), "mature neutrophils" (mature_NEUT), and myeloid-to-erythroid (M:E) ratio were compared with cytologic evaluation. Intra-assay repeatability and total error (TE) were calculated for both methods. Intra-assay repeatability was 0.95-2.48% for the XT-2000iV and 8.32-23.23% for cytology. Observed TE for the automated measurement was 5.16-46.8% and for cytology 22.70-76.74%. Spearman rank correlation was excellent for M:E ratio (0.91) and fair for the other populations (0.65-0.71). Absolute bias for M:E ratio was low (-0.114). A negative absolute bias of -7.71% for the XT-2000iV was found for poly_orth_NRBC, whereas the bias was positive for total_NEUT (7.10%) and mature_NEUT (14.67%). M:E ratio of canine bone marrow samples can be precisely determined using the Sysmex XT-2000iV WBC/BASO channel. Total_NRBC, poly_orth_NRBC, total_NEUT, and mature_NEUT can be estimated rapidly. With distinctly lower coefficient of variation and observed TE compared with cytology, automated measurement provides advantages in terms of standardization, and it is suited to the advanced preclinical research environment where large numbers of samples are investigated.
Merck KGaA, Global Non-Clinical Safety, Global Early Development, Darmstadt, Germany (Pernecker, Johannes).|Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig University Giessen, Giessen, Germany (Bauer, Moritz).|IDEXX BioResearch Europe, A Division of IDEXX Laboratories, Ludwigsburg, Germany (Ginder).|Global Preclinical Development & Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany (Harleman).
Iris
I
Pernecker
Merck KGaA, Global Non-Clinical Safety, Global Early Development, Darmstadt, Germany (Pernecker, Johannes).|Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig University Giessen, Giessen, Germany (Bauer, Moritz).|IDEXX BioResearch Europe, A Division of IDEXX Laboratories, Ludwigsburg, Germany (Ginder).|Global Preclinical Development & Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany (Harleman).
Natali B
NB
Bauer
Merck KGaA, Global Non-Clinical Safety, Global Early Development, Darmstadt, Germany (Pernecker, Johannes).|Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig University Giessen, Giessen, Germany (Bauer, Moritz).|IDEXX BioResearch Europe, A Division of IDEXX Laboratories, Ludwigsburg, Germany (Ginder).|Global Preclinical Development & Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany (Harleman).
Sigrid
S
Johannes
Merck KGaA, Global Non-Clinical Safety, Global Early Development, Darmstadt, Germany (Pernecker, Johannes).|Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig University Giessen, Giessen, Germany (Bauer, Moritz).|IDEXX BioResearch Europe, A Division of IDEXX Laboratories, Ludwigsburg, Germany (Ginder).|Global Preclinical Development & Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany (Harleman).
Melanie
M
Ginder
Merck KGaA, Global Non-Clinical Safety, Global Early Development, Darmstadt, Germany (Pernecker, Johannes).|Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig University Giessen, Giessen, Germany (Bauer, Moritz).|IDEXX BioResearch Europe, A Division of IDEXX Laboratories, Ludwigsburg, Germany (Ginder).|Global Preclinical Development & Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany (Harleman).
Johannes H
JH
Harleman
Merck KGaA, Global Non-Clinical Safety, Global Early Development, Darmstadt, Germany (Pernecker, Johannes).|Department of Veterinary Clinical Sciences, Clinical Pathology and Clinical Pathophysiology, Justus-Liebig University Giessen, Giessen, Germany (Bauer, Moritz).|IDEXX BioResearch Europe, A Division of IDEXX Laboratories, Ludwigsburg, Germany (Ginder).|Global Preclinical Development & Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany (Harleman).
Andreas
A
Moritz
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D002452:Cell Count / Q000295:instrumentation / Q000662:veterinary*; D004285:Dogs / Q000033:anatomy & histology*; D004900:Erythroblasts / Q000166:cytology; D041905:Erythroid Cells / Q000166:cytology; D005260:Female; D005434:Flow Cytometry / Q000295:instrumentation / Q000662:veterinary; D006403:Hematologic Tests / Q000295:instrumentation / Q000662:veterinary*; D008297:Male; D022423:Myeloid Cells / Q000166:cytology; D009504:Neutrophils / Q000166:cytology; D015203:Reproducibility of Results
Bone marrow; Sysmex; cytology; dogs; flow cytometry; preclinical safety